BIOLASE logoBIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIOL
  • CUSIP: N/A
  • Web:
  • Market Cap: $79.16 million
  • Outstanding Shares: 67,660,000
Average Prices:
  • 50 Day Moving Avg: $1.26
  • 200 Day Moving Avg: $1.46
  • 52 Week Range: $0.80 - $1.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.70
  • P/E Growth: -0.43
Sales & Book Value:
  • Annual Revenue: $51.67 million
  • Price / Sales: 1.53
  • Book Value: $0.27 per share
  • Price / Book: 4.33
  • EBIDTA: ($13,600,000.00)
  • Net Margins: -25.50%
  • Return on Equity: -53.73%
  • Return on Assets: -30.49%
  • Current Ratio: 2.27%
  • Quick Ratio: 1.44%
  • Average Volume: 65,044 shs.
  • Beta: 1.89
  • Short Ratio: 32.73

Frequently Asked Questions for BIOLASE (NASDAQ:BIOL)

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) posted its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.03. The company earned $10.87 million during the quarter. BIOLASE had a negative return on equity of 53.73% and a negative net margin of 25.50%. View BIOLASE's Earnings History.

Where is BIOLASE's stock going? Where will BIOLASE's stock price be in 2017?

1 brokers have issued twelve-month target prices for BIOLASE's shares. Their predictions range from $2.50 to $2.50. On average, they expect BIOLASE's share price to reach $2.50 in the next year. View Analyst Ratings for BIOLASE.

Are investors shorting BIOLASE?

BIOLASE saw a decline in short interest during the month of April. As of April 28th, there was short interest totalling 2,505,302 shares, a decline of 1.4% from the April 13th total of 2,541,687 shares. Based on an average daily volume of 63,377 shares, the short-interest ratio is currently 39.5 days.

Who are some of BIOLASE's key competitors?

Who owns BIOLASE stock?

BIOLASE's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Oracle Investment Management Inc. (21.64%), Vanguard Group Inc. (2.35%), Birchview Capital LP (1.90%), Granite Investment Partners LLC (1.48%), Teton Advisors Inc. (0.51%) and Trellus Management Company LLC (0.43%). Company insiders that own BIOLASE stock include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Institutional Ownership Trends for BIOLASE.

Who sold BIOLASE stock? Who is selling BIOLASE stock?

BIOLASE's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for BIOLASE.

Who bought BIOLASE stock? Who is buying BIOLASE stock?

BIOLASE's stock was purchased by a variety of institutional investors in the last quarter, including Trellus Management Company LLC, Granite Investment Partners LLC, Geode Capital Management LLC and Vanguard Group Inc.. Company insiders that have bought BIOLASE stock in the last two years include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Insider Buying and Selling for BIOLASE.

How do I buy BIOLASE stock?

Shares of BIOLASE can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BIOLASE stock cost?

One share of BIOLASE stock can currently be purchased for approximately $1.17.

Analyst Ratings

Consensus Ratings for BIOLASE (NASDAQ:BIOL) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (113.68% upside)

Analysts' Ratings History for BIOLASE (NASDAQ:BIOL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/25/2017Singular ResearchInitiated CoverageBuy$2.50LowView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for BIOLASE (NASDAQ:BIOL)
Earnings by Quarter for BIOLASE (NASDAQ:BIOL)
Earnings History by Quarter for BIOLASE (NASDAQ:BIOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.03)($0.06)$10.87 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.02($0.06)$13.76 millionViewListenView Earnings Details
11/8/2016Q316($0.02)($0.05)$12.40 million$13.20 millionViewListenView Earnings Details
5/9/2016Q116($0.03)($0.07)$11.90 million$11.00 millionViewN/AView Earnings Details
3/9/2016Q415($0.09)($0.04)$13.90 million$14.50 millionViewN/AView Earnings Details
11/4/2015Q315($0.08)($0.09)$1.50 million$11.20 millionViewN/AView Earnings Details
11/4/2014Q314($0.09)($0.08)$11.70 million$12.70 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.17)$12.97 million$10.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.11)$13.29 million$11.50 millionViewN/AView Earnings Details
3/5/2014Q413($0.04)($0.04)$15.67 million$15.20 millionViewN/AView Earnings Details
11/5/2013Q313($0.05)($0.10)$16.42 million$12.30 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.04)($0.06)$15.69 million$14.20 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.06)$14.48 million$14.60 millionViewN/AView Earnings Details
3/6/2013Q4 2012$0.05$18.03 million$19.10 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BIOLASE (NASDAQ:BIOL)
Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS


Dividend History for BIOLASE (NASDAQ:BIOL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BIOLASE (NASDAQ:BIOL)
Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 34.15%
Insider Trades by Quarter for BIOLASE (NASDAQ:BIOL)
Institutional Ownership by Quarter for BIOLASE (NASDAQ:BIOL)
Insider Trades by Quarter for BIOLASE (NASDAQ:BIOL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2016Jack W SchulerMajor ShareholderBuy500$0.80$400.00View SEC Filing  
2/17/2016Jack W SchulerMajor ShareholderBuy4,100$0.80$3,280.00View SEC Filing  
2/12/2016Jack W SchulerMajor ShareholderBuy19,080$0.76$14,500.80View SEC Filing  
2/10/2016Jack W SchulerMajor ShareholderBuy67,213$0.78$52,426.14View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy1,400$0.80$1,120.00View SEC Filing  
1/22/2016Jack W SchulerMajor ShareholderBuy6,670$0.78$5,202.60View SEC Filing  
1/20/2016Jack W SchulerMajor ShareholderBuy24,200$0.75$18,150.00View SEC Filing  
12/28/2015Jack W SchulerMajor ShareholderBuy18,350$0.79$14,496.50View SEC Filing  
12/24/2015Jack W SchulerMajor ShareholderBuy41,900$0.76$31,844.00View SEC Filing  
12/22/2015Jack W SchulerMajor ShareholderBuy87,200$0.74$64,528.00View SEC Filing  
12/21/2015Jack W SchulerMajor ShareholderBuy127,892$0.73$93,361.16View SEC Filing  
12/17/2015Jack W SchulerMajor ShareholderBuy34,158$0.70$23,910.60View SEC Filing  
11/11/2015Larry N FeinbergMajor ShareholderBuy54,800$0.79$43,292.00View SEC Filing  
11/10/2015Paul N ClarkDirectorBuy134,579$0.75$100,934.25View SEC Filing  
9/24/2015David C DreyerCFOBuy5,000$1.20$6,000.00View SEC Filing  
9/22/2015David C DreyerCFOBuy5,000$1.37$6,850.00View SEC Filing  
9/17/2015David C DreyerCFOBuy10,000$1.45$14,500.00View SEC Filing  
11/3/2014Jeffrey M NugentCEOBuy40,465$2.39$96,711.35View SEC Filing  
11/3/2014Jonathan T Md LordDirectorBuy101,163$2.39$241,779.57View SEC Filing  
11/3/2014Larry N FeinbergMajor ShareholderBuy2,067,979$2.39$4,942,469.81View SEC Filing  
7/22/2014Alexander K ArrowCOOBuy7,812$1.92$14,999.04View SEC Filing  
7/22/2014Frederick D FurryCFOBuy13,020$1.92$24,998.40View SEC Filing  
7/22/2014Jeffrey M NugentCEOBuy52,083$1.92$99,999.36View SEC Filing  
7/22/2014Paul N ClarkDirectorBuy520,833$1.92$999,999.36View SEC Filing  
7/18/2014Larry N FeinbergMajor ShareholderBuy2,270,836$1.92$4,360,005.12View SEC Filing  
2/12/2014Larry N FeinbergMajor ShareholderBuy2,035,033$2.57$5,230,034.81View SEC Filing  
1/31/2014Larry Feinbergmajor shareholderBuy30,798$2.45$75,455.10View SEC Filing  
12/19/2013Larry Feinbergmajor shareholderBuy340,000$1.80$612,000.00View SEC Filing  
12/17/2013Larry Feinbergmajor shareholderBuy150,400$1.87$281,248.00View SEC Filing  
8/23/2012Frederick D FurryCFOBuy5,075$1.64$8,323.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BIOLASE (NASDAQ:BIOL)
Latest Headlines for BIOLASE (NASDAQ:BIOL)
DateHeadline logoETFs with exposure to BIOLASE, Inc. : May 22, 2017 - May 22 at 3:52 PM logoShort Interest in BIOLASE Inc (BIOL) Drops By 1.4% - May 13 at 7:08 PM logoETFs with exposure to BIOLASE, Inc. : May 11, 2017 - May 11 at 4:28 PM logoBIOLASE, Inc. :BIOL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 3:56 PM logoBIOLASE Announces Management Change - May 5 at 3:56 PM logoBIOLASE Inc (BIOL) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - May 4 at 9:00 PM logoEdited Transcript of BIOL earnings conference call or presentation 3-May-17 8:30pm GMT - May 4 at 4:03 PM logoBIOLASE Reports 2017 First Quarter Results - May 3 at 6:14 PM logoBiolase reports 1Q loss - May 3 at 6:05 PM logoSomewhat Favorable Media Coverage Somewhat Likely to Impact BIOLASE (BIOL) Share Price - May 2 at 11:26 PM logoBIOLASE Inc (BIOL) Scheduled to Post Quarterly Earnings on Wednesday - May 1 at 1:18 PM logoBIOLASE (BIOL) Earning Somewhat Favorable News Coverage, Report Finds - April 26 at 2:32 PM logoBIOLASE® to Host 2017 First Quarter Financial Results Conference Call on May 3 - April 26 at 12:27 PM logoBIOLASE Inc (BIOL) Coverage Initiated at Singular Research - April 25 at 3:06 PM logoForm 4 BIOLASE, INC For: Apr 18 Filed by: LORD JONATHAN T MD - April 19 at 9:14 PM logoBIOLASE (BIOL) Earning Somewhat Favorable Media Coverage, Report Finds - April 17 at 5:25 PM logoBIOLASE (BIOL) Earning Positive News Coverage, Report Shows - April 14 at 5:40 PM logoBIOLASE to Raise $10.5 Million from Institutional and Individual Investors in a Private Placement - April 13 at 4:03 PM logoREGISTER TODAY: Multidisciplinary Treatment Solutions for Peri-Implantitis Symposium - April 7 at 3:52 PM logoBIOLASE to Showcase Two New Game-Changing Products at International Dental Show in Cologne - March 20 at 11:08 AM logoBIOLASE, INC Financials - March 16 at 3:22 PM logoBIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - March 14 at 8:41 AM logoBIOLASE Names James D. Surek Vice President Sales, Americas - March 13 at 11:12 AM logoBIOLASE, INC Files SEC form 10-K, Annual Report - March 10 at 4:44 PM logoBIOLASE to Present at the 29th Annual ROTH Conference - March 9 at 4:27 PM logoBRIEF-Biolase Q4 loss per share $0.07 - March 9 at 2:42 AM logoQ4 2016 BIOLASE Inc Earnings Release - After Market Close - March 8 at 4:40 PM logoQ4 2016 BIOLASE Inc Earnings Release - After Market Close - March 8 at 4:40 PM logoBIOLASE Reports 2016 Full Year and Fourth Quarter Results - March 8 at 4:40 PM logoBIOLASE Reports 2016 Full Year and Fourth Quarter Results - March 8 at 4:40 PM logoBIOLASE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 8 at 4:40 PM logoBIOLASE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 8 at 4:40 PM logoBIOLASE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer - March 1 at 8:55 PM logoBIOLASE® to Host 2016 Fourth Quarter Financial Results Conference Call on March 8 - March 1 at 8:39 AM logoBIOLASE, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - February 22 at 4:00 PM logoBIOLASE to Host ‘Lasers for Every Dentist’ Launch Celebration at Chicago Midwinter Dental Meeting - February 21 at 10:41 AM logoBIOLASE Announces the FDA Clearance and Worldwide Launch of New Waterlase Express™ All-Tissue Laser System - February 10 at 3:24 PM logo6:01 am Biolase receives 510(k) clearance for its fifth-generation Waterlas Express for commercial distribution from the FDA in the U.S. as well as select international markets in Europe, the Middle East and Asia - February 10 at 3:24 PM logoBIOLASE Announces the FDA Clearance and Worldwide Launch of Its New Epic Pro™ Diode Laser System - Business Wire (press release) - January 25 at 4:24 PM



BIOLASE (BIOL) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff